A study found that PD-L1, PD-L2 and tumor mutation burden from a comprehensive genomic and transcriptomic profiling test independently predicted Keytruda (pembrolizumab) benefit in pan-solid tumors—and when combined in a multivariate signature score—predicted benefit better than PD-L1 or TMB alone.
The NCI Human Tumor Atlas Network (HTAN) has published a cluster of papers intended to advance the framework of spatial omics, the science of profiling morphological and molecular features of human cancers in two and three dimensions.
